Table 4.

Mixed modeling^a showing unadjusted longitudinal associations between FcRγ⁻ CD56^dim FcRγ⁻ NK cell levels and immune parameters in HIV⁺ individuals (n = 20).

Immune parameter	b(SE)	95% CI	Wald χ2	p-Value
T cell activation
CD4+ (% HLA DR+/CD38+)	0.33 (0.66)	−0.96, 1.62	χ2(1) = 0.26	0.613
CD8+ (% HLA DR+/CD38+)	0.01 (0.21)	−0.40, 0.41	χ2(1) = 0.00	0.977
NK cell activation/function
NK (% CD69+)	0.62 (0.46)	−0.29,1.52	χ2(1) = 1.78	0.182
NK (% HLA DR+/CD38+)	−0.24 (0.63)	−1.46, 0.99	χ2(1) = 0.14	0.705
Monocyte subsets
% Classical monocytes	−0.13 (0.20)	−0.51, 0.26	χ2(1) = 0.42	0.519
% Intermediate monocytes	0.35 (0.46)	−0.55, 1.25	χ2(1) = 0.59	0.444
% Non-classical monocytes	0.14 (0.30)	−0.44, 0.72	χ2(1) = 0.23	0.631
Soluble markers
HCMV lysate IgG (AU)	2.4 × 10−5 (4.9 × 10−5)	−7.3 × 10−5, 1.2 × 10−4	χ2(1) = 0.23	0.631
HCMV gB IgG (AU)	2.7 × 10−5 (2.9 × 10−5)	−2.9 × 10−5, 8.4 × 10−5	χ2(1) = 0.89	0.345
CXCL10 (pg/mL)	2.7 × 10−3 (0.01)	−0.02, 0.03	χ2(1) = 0.05	0.828
sCD163 (ng/mL)	3.5 × 10−3 (2.2 × 10−3)	−8.7 × 10−4, 7.9 × 10−3	χ2(1) = 2.47	0.116

Regression coefficient (b), SE, 95% confidence intervals (95% CI), Wald test (Wald χ²), and probability value (p-value).

^aLinear mixed modeling specifying a random intercept for study participant to account for the dependency associated with repeated measurements (i.e., all participant observations were used in analyses).

AU, arbitrary units.